-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-01-2026 TO 02-07-2026
The Groundhog sees his shadow, so hunker down and trade more to warm up! 😉 We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions…
$AMGN, $AZN, $BMY, $BSX, $DNLI, $GKOS, $GSK, $INCY, $JAZZ, $LLY, $MRNA, $PHVS, $REGN, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases -
Hoth Therapeutics Reports Significant Initial Results in Novel Cancer Therapy Trial
NASDAQ: $HOTH A recent press release from PR Newswire highlights exciting early data from Hoth Therapeutics regarding their ongoing clinical study involving a novel treatment approach for cancer patients whose tumors express the Epidermal Growth Factor Receptor (EGFR). The announcement, specifically concerning the open-label pharmacokinetic (PK) cohort of the study, signals a promising step forward…
-
SweetWater Brewing Announces ‘Big Trip’ Double IPA: A Bold New Flavor for Craft Beer Enthusiasts
NASDAQ: $TLRY Craft beer aficionados, get ready to mark your calendars! SweetWater Brewing Company, known for its distinctive style and commitment to quality brewing, has just announced the arrival of a highly anticipated new addition to its lineup: the Big Trip Double IPA. This news, officially released via a press statement on January 22, 2026,…
-
PDS Biotech Secures New U.S. Patent for Core Technology
NASDAQ: $PDSB Pharmaceutical development is a meticulous and often lengthy process, where intellectual property protection is paramount to innovation. In a significant move for the sector, PDS Biotech recently announced the issuance of a new U.S. Patent. This patent specifically covers the fundamental technology platform that underpins one of the company’s key investigational products, PDS0.…
-
Lexicon Pharmaceuticals Advances Pilavapadin Towards Late-Stage Trials for Diabetic Neuropathic Pain
NASDAQ: $LXRX Lexicon Pharmaceuticals recently shared significant news regarding its investigational drug, pilavapadin, marking a crucial step forward in the potential treatment landscape for diabetic peripheral neuropathic pain (DPNP). The company announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Understanding the Significance of the FDA Meeting…
-
Legend Biotech Announces Key Data Presentation for CARVYKTI at 2026 Tandem Meetings
NASDAQ: $LEGN Advancing the Frontier: Legend Biotech Prepares for Major Data Showcase Legend Biotech Corporation (NASDAQ: $LEGN) has recently announced an important upcoming event that underscores their commitment to innovative cancer therapies. According to a press release dated January 21, 2026, the company will be presenting new data concerning its groundbreaking therapy, CARVYKTI® (ciltacabtagene autoleucel),…
-
Progress Report: Aligos Therapeutics’ SUPREME Trial in Hepatitis B
NASDAQ: $ALGS Aligos Therapeutics recently issued an update concerning the progress of its Phase 2b SUPREME study, a significant development in the ongoing effort to find effective treatments for chronic Hepatitis B virus (HBV) infection. For those following pharmaceutical advancements in virology, this announcement provides valuable insight into the trajectory of their lead candidate. The…
-
A Significant Advance in RRP Treatment: Papizimeos Reaches New Standard of Care Status
NASDAQ: $PGEN A landmark development in the treatment of Recurrent Respiratory Papillomatosis (RRP) has recently been announced, marking a potential shift in clinical practice for thousands of patients worldwide. A new expert consensus, formally published in the prestigious medical journal, The Laryngoscope, strongly recommends Papizimeos (zopapogene imadenovec) as the new standard of care for first-line…
-
Orphai Therapeutics’ LAM-001 Study Chosen for Key Presentation at ATS 2026
Orphai Therapeutics has achieved a significant milestone this week with the announcement that their Phase 2a clinical trial data for LAM-001 will be presented orally at the prestigious American Thoracic Society (ATS) 2026 International Conference. This selection is a strong indicator of the potential importance of their findings within the respiratory medicine community. Understanding the…